Knockdown of CRAD suppresses the growth and promotes the apoptosis of human lung cancer cells via Claudin 4.
A549 Cells
Apoptosis
/ genetics
Carcinoma, Non-Small-Cell Lung
/ genetics
Cell Cycle
/ genetics
Cell Proliferation
/ genetics
Claudin-4
/ genetics
Computational Biology
DNA Damage
DNA Repair
/ genetics
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Gene Knockdown Techniques
Humans
Lung
/ pathology
Lung Neoplasms
/ genetics
Microfilament Proteins
/ genetics
Oligonucleotide Array Sequence Analysis
Signal Transduction
/ genetics
Up-Regulation
Apoptosis
CARD
Claudin 4
NSCLC
Proliferation
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
30 10 2020
30 10 2020
Historique:
received:
09
04
2020
revised:
30
09
2020
accepted:
01
10
2020
pubmed:
3
10
2020
medline:
15
4
2021
entrez:
2
10
2020
Statut:
ppublish
Résumé
Non-small cell lung cancer (NSCLC) is one of the most common causes of cancer-related mortality globally. However, the mechanism underlying NSCLC is not fully understood. Here, we investigated the role of cancer-related regulator of actin dynamics (CRAD) in NSCLC. We showed that CRAD was up-regulated in human NSCLC tissues and lung cancer cell lines. Lentivirus-mediated knockdown of CRAD repressed the proliferation and colony growth of A549 and H1299 cells. Apoptosis was enhanced by CRAD silencing in both cells, implicating that CRAD might maintain the survival of lung cancer cells. Microarray and bioinformatic assay revealed that CRAD directly or indirectly regulated diverse genes, including those involved in cell cycle and DNA damage repair. qRT-PCR and Western blot results confirmed the dysregulated genes as shown in microarray analysis. Claudin 4 was up-regulated in CRAD silenced A549 cells. The knockdown of Claudin 4 blocked the effects of CRAD on the expression of cell cycle and apoptosis effectors and enhanced the viability of A549 cells with CRAD down-regulation. Taken together, our findings demonstrate that CRAD acts as an oncogene in NSCLC at least partly through repressing Claudin 4.
Identifiants
pubmed: 33006362
pii: 226565
doi: 10.1042/BSR20201140
pmc: PMC7560521
pii:
doi:
Substances chimiques
CLDN4 protein, human
0
CRACD protein, human
0
Claudin-4
0
Microfilament Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2020 The Author(s).
Références
Biosci Rep. 2018 Oct 5;38(5):
pubmed: 30232236
Biosci Rep. 2020 Jun 26;40(6):
pubmed: 32432658
Biosci Rep. 2014 Jul 29;34(4):
pubmed: 24965943
FEBS Lett. 2018 Nov;592(22):3658-3669
pubmed: 29935019
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
F1000Res. 2019 Nov 25;8:
pubmed: 31824651
Cell. 2016 Jun 2;165(6):1401-1415
pubmed: 27180906
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Oncotarget. 2016 Apr 26;7(17):24719-33
pubmed: 27034160
Trends Cell Biol. 2020 Sep;30(9):720-735
pubmed: 32674938
Biochem Biophys Res Commun. 2013 Nov 22;441(3):661-7
pubmed: 24161395
Nat Cell Biol. 2018 Nov;20(11):1232-1233
pubmed: 30361696
J Hematol Oncol. 2014 Dec 05;7:87
pubmed: 25477004
Biosci Rep. 2020 Jan 31;40(1):
pubmed: 31894837
Nat Cell Biol. 2018 Nov;20(11):1303-1314
pubmed: 30361697
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
Nat Rev Dis Primers. 2015 May 21;1:15009
pubmed: 27188576
Exp Physiol. 2020 Jun;105(6):979-988
pubmed: 31856376
Int Rev Cell Mol Biol. 2019;346:129-155
pubmed: 31122393
J Cardiovasc Dev Dis. 2019 Jun 22;6(2):
pubmed: 31234534
Biosci Rep. 2020 Jul 31;40(7):
pubmed: 32696949
Mol Cancer Res. 2019 Mar;17(3):741-750
pubmed: 30606772
Cancer Lett. 2013 May 10;332(1):3-10
pubmed: 23348699
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
Nat Cell Biol. 2017 Feb;19(2):85-93
pubmed: 28114272
Cancer Cell. 2019 Jan 14;35(1):33-45.e6
pubmed: 30645975
Oncotarget. 2019 Mar 15;10(22):2189-2202
pubmed: 31040910
Biosci Rep. 2020 Apr 30;40(4):
pubmed: 32266933
BMC Cancer. 2016 Oct 11;16(1):788
pubmed: 27724921
Int J Cancer. 2018 Aug 15;143(4):931-943
pubmed: 29516506
Sci Transl Med. 2017 Nov 8;9(415):
pubmed: 29118260
Nat Commun. 2016 Aug 31;7:12604
pubmed: 27576662
Future Oncol. 2016 Apr;12(7):931-43
pubmed: 26882955